Thoughts on the impact of SOLO2 - olaparib maintenance in recurrent #BRCA mutant #ovariancancer - this randomized trial demonstrated an overall survival benefit in this population - the first trial of #PARPi to achieve this! #ASCO20 #SGOatASCO #gyncsm

Importantly, the overall survival benefit held up even when patients in the placebo arm went on to receive a #PARPi as a later line of therapy - this provides further evidence that sequencing matters - and for PARP - earlier is better. #ASCO20 #SGOatASCO #gyncsm

28% of patients that received olaparib had not received a subsequent therapy at 5 YEARS! This is an incredible figure about the durability of activity! #ASCO20 #SGOatASCO #gyncsm

Adverse events were as expected in the olaparib arm - although the discontinuation rate did go up over time #ASCO20 #SGOatASCO #gyncsm

The rate of AML/MDS has gone up in the final analysis to 8% - this needs to be explored further - who were these patients? When did the diagnosis occur? How can we ensure we are protecting patients? #ASCO20 #SGOatASCO #gyncsm

Bottom line - olaparib as a maintanence therapy for #BRCA mutant recurrent #ovariancancer provides an overall survival benefit! We are making progress #ASCO20 #SGOatASCO #gyncsm